Benjamin Ole Wolthers
Overview
Explore the profile of Benjamin Ole Wolthers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sagi J, Gezsi A, Egyed B, Jakab Z, Benedek N, Attarbaschi A, et al.
Cancers (Basel)
. 2021 Jun;
13(10).
PMID: 34066083
Despite improving cure rates in childhood acute lymphoblastic leukemia (ALL), therapeutic side effects and relapse are ongoing challenges. These can also affect the central nervous system (CNS). Our aim was...
2.
Geybels M, Wolthers B, Kreiner F, Rasmussen S, Bauer R
BMC Med Inform Decis Mak
. 2021 May;
21(1):164.
PMID: 34016120
Background: Robust identification of surrogate endpoints can help accelerate the development of pharmacotherapies for diseases traditionally evaluated using true endpoints associated with prolonged follow-up. The meta-analysis-based surrogate endpoint evaluation (SEE)...
3.
Baruchel A, Brown P, Rizzari C, Silverman L, Van der Sluis I, Wolthers B, et al.
ESMO Open
. 2020 Sep;
5(5):e000977.
PMID: 32967920
Insufficient exposure to asparaginase therapy is a barrier to optimal treatment and survival in childhood acute lymphoblastic leukaemia (ALL). Three important reasons for inactivity or discontinuation of asparaginase therapy are...
4.
Tulstrup M, Moriyama T, Jiang C, Grosjean M, Nersting J, Abrahamsson J, et al.
Blood
. 2020 May;
136(10):1161-1168.
PMID: 32391884
Methotrexate (MTX) during maintenance therapy is essential for curing acute lymphoblastic leukemia (ALL), but dosing strategies aiming at adequate treatment intensity are challenged by interindividual differences in drug disposition. To...
5.
Mogensen P, Grell K, Schmiegelow K, Overgaard U, Wolthers B, Mogensen S, et al.
PLoS One
. 2020 Apr;
15(4):e0231209.
PMID: 32251440
As survival of acute lymphoblastic leukemia (ALL) exceeds 90%, limiting therapy-related toxicity has become a key challenge. Cardio-metabolic dysfunction is a challenge during and after childhood ALL therapy. In a...
6.
Wolthers B, Mogensen P, Frandsen T, Abrahamsson J, Behrendtz M, Heyman M, et al.
Pediatr Blood Cancer
. 2018 Sep;
66(1):e27437.
PMID: 30216644
Pancreatitis is a frequent toxicity to acute lymphoblastic leukemia (ALL) treatment, significantly associated with asparaginase use, and may be followed by severe complications such as acute hyperglycaemia, need for mechanical...
7.
Tulstrup M, Grosjean M, Nygaard Nielsen S, Grell K, Wolthers B, Wegener P, et al.
Leukemia
. 2018 Sep;
32(12):2527-2535.
PMID: 30201983
The antileukaemic drug 6-mercaptopurine is converted into thioguanine nucleotides (TGN) and incorporated into DNA (DNA-TG), the active end metabolite. In a series of genome-wide association studies, we analysed time-weighted means...
8.
Schmiegelow K, Muller K, Mogensen S, Mogensen P, Wolthers B, Stoltze U, et al.
F1000Res
. 2017 Apr;
6:444.
PMID: 28413626
During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both),...
9.
Wolthers B, Thiested E, Gyhrs A
Ugeskr Laeger
. 2015 Jan;
177(2A):10-1.
PMID: 25612944
This case report describes how a three-year-old girl referred to our paediatric ward, infected with varicella-zoster virus and a bacterial pneumonia causing atelectasis. The girl did not respond to initial...